Update on type 2 diabetes mellitus: Understanding changes in the diabetes treatment paradigm

International Journal of Clinical Practice

Volumn 61, Issue SUPPL. 154, 2007, Pages 3-11

  Green, J ^a   Feinglos, M ^a  

^a DUKE UNIVERSITY MEDICAL CENTER   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

2,4 THIAZOLIDINEDIONE DERIVATIVE; ANTIOBESITY AGENT; DIPEPTIDYL PEPTIDASE IV INHIBITOR; EXENDIN 4; GLIBENCLAMIDE; GLUCAGON LIKE PEPTIDE 1; INCRETIN; INSULIN; INSULIN SENSITIZING AGENT; METFORMIN; PIOGLITAZONE; RIMONABANT; ROSIGLITAZONE; SITAGLIPTIN; SULFONYLUREA; TETRAHYDROLIPSTATIN; TROGLITAZONE; VILDAGLIPTIN; ANTIDIABETIC AGENT;

ADD ON THERAPY; CELL FUNCTION; CLINICAL TRIAL; DIAGNOSTIC TEST; DISEASE COURSE; DOSE RESPONSE; DRUG ABSORPTION; DRUG BINDING; DRUG CLASSIFICATION; DRUG EFFICACY; DRUG EXCRETION; DRUG METABOLISM; DRUG SAFETY; DRUG SYNTHESIS; DYSLIPIDEMIA; GASTROINTESTINAL SYMPTOM; GLUCOSE BLOOD LEVEL; HUMAN; INSULIN RESISTANCE; LIFESTYLE MODIFICATION; LONG TERM CARE; MEDICAL PRACTICE; MONOTHERAPY; NON INSULIN DEPENDENT DIABETES MELLITUS; NONHUMAN; OBESITY; PANCREAS ISLET BETA CELL; PANCREAS ISLET DISEASE; PATHOPHYSIOLOGY; PRACTICE GUIDELINE; PRIORITY JOURNAL; REVIEW; TREATMENT CONTRAINDICATION; TREATMENT DURATION; TREATMENT PLANNING; URINARY EXCRETION; PANCREAS ISLET; PHYSIOLOGY;

ANTI-OBESITY AGENTS; DIABETES MELLITUS, TYPE 2; HUMANS; HYPOGLYCEMIC AGENTS; INCRETINS; ISLETS OF LANGERHANS;

EID: 85047698149     PISSN: 13685031     EISSN: 17421241     Source Type: Journal    
DOI: 10.1111/j.1742-1241.2007.01438.x     Document Type: Review

References (55)

1. US Centers for Disease Control and Prevention. Diabetes Public Health Resource. Data & Trends: Prevalence of Diabetes. http://www.cdc.gov/ diabetes/statistics/prev/national/figpersons.htm (accessed March 2007).
2. Gerich JE. Redefining the clinical management of type 2 diabetes: matching therapy to pathophysiology. Eur J Clin Invest 2002 32 (Suppl. 3 46 53.
3. Hogan P, Dall T, Nikolov P American Diabetes Association. Economic costs of diabetes in the US in 2002. Diabetes Care 2003 26 : 917 32.
4. Saydah SH, Fradkin J, Cowie CC. Poor control of risk factors for vascular disease among adults with previously diagnosed diabetes. JAMA 2004 291 : 335 42.
5. Stratton IM, Adler AI, Neil HA et al. Association of glycemia with macrovascular and microvascular complications of type 2 diabetes (UKPDS 35): prospective observational study. BMJ 2000 321 : 405 12.
6. American Diabetes Association. Standards of medical care in diabetes - 2006. Diabetes Care 2006 29 (Suppl. 1 S4 42.
7. Nathan DM, Buse JB, Davidson MB et al. Management of hyperglycemia in type 2 diabetes: a consensus algorithm for the initiation and adjustment of therapy. Diabetes Care 2006 29 : 1963 72.
8. Barnett AH. Treating to goal: challenges of current management. Eur J Endocrinol 2004 151 (Suppl. 2 T3 7 discussion T29 30.
9. U.K. Prospective Diabetes Study Group. U.K. prospective diabetes study 16: overview of 6 years' therapy of type II diabetes: a progressive disease. Diabetes 1995 44 : 1249 58.
10. Turner RC, Cull CA, Frighi V et al. Glycemic control with diet, sulfonylurea, metformin, or insulin in patients with type 2 diabetes mellitus: progressive requirement for multiple therapies (UKPDS 49). JAMA 1999 281 : 2005 12.
11. Gerich JE. Contributions of insulin-resistance and insulin-secretory defects to the pathogenesis of type 2 diabetes mellitus. Mayo Clin Proc 2003 78 : 447 56.
12. Kahn SE. The relative contributions of insulin resistance and beta-cell dysfunction to the pathophysiology of type 2 diabetes. Diabetologia 2003 46 : 3 19.
13. Aronoff SL, Berkowitz K, Shreiner B, Want L. Glucose metabolism and regulation: beyond insulin and glucagon. Diabetes Spectrum 2004 17 : 183 90.
14. Del Prato S, Marchetti P. Beta- and alpha-cell dysfunction in type 2 diabetes. Horm Metab Res 2004 36 : 775 81.
15. Nauck M, Stockmann F, Ebert R, Creutzfeldt W. Reduced incretin effect in type 2 (non-insulin-dependent) diabetes. Diabetologia 1986 29 : 46 52.
16. Drucker DJ. Enhancing incretin action for the treatment of type 2 diabetes. Diabetes Care 2003 26 : 2929 40.
17. Nauck MA, Kleine N, Orskov C, Holst JJ, Willms B, Creutzfeldt W. Normalization of fasting hyperglycaemia by exogenous glucagon-like peptide 1 (7-36 amide) in type 2 (non-insulin-dependent) diabetic patients. Diabetologia 1993 36 : 741 4.
18. Holst JJ. Therapy of type 2 diabetes mellitus based on the actions of glucagon-like peptide-1. Diabetes Metab Res Rev 2002 18 : 430 41.
19. Riddle MC. Glycemic management of type 2 diabetes: an emerging strategy with oral agents, insulins, and combinations. Endocrinol Metab Clin N Am 2005 34 : 77 98.
20. Krentz AJ, Bailey CJ. Oral antidiabetic agents. Drugs 2005 65 : 385 411.
21. Inzucchi SE. Oral antihyperglycemic therapy for type 2 diabetes. JAMA 2002 287 : 360 72.
22. Rendell M. The role of sulphonylureas in the management of type 2 diabetes mellitus. Drugs 2004 64 : 1339 1358.
23. Wright A, Burden ACF, Paisey RB, et al. Sulfonylurea inadequacy: efficacy of addition of insulin over 6 years in patients with type 2 diabetes in the U.K. Prospective Diabetes Study (UKPDS 57). Diabetes Care 2002 25 : 330 336.
24. Matthews DR, Cull CA, Stratton IM, et al. UKPDS 26: sulphonylurea failure in non-insulin-dependent diabetic patients over six years. UK Prospective Diabetes Study (UKPDS) Group. Diabet Med 1998 15 : 297 303.
25. Kahn SE, Haffner SM, Heise MA, et al. Glycemic durability of rosiglitazone, metformin, or glyburide monotherapy. N Engl J Med 2006 355 : 2427 2443.
26. Hanefeld M, Sachse G. The effects of orlistat on body weight and glycaemic control in overweight patients with type 2 diabetes: a randomized, placebo-controlled trial. Diabetes Obes Metab 2002 4 : 415 423.
27. Miles JM, Leiter L, Hollander P, et al. Effect of orlistat in overweight and obese patients with type 2 diabetes treated with metformin. Diabetes Care 2002 25 : 1123 1128.
28. Kelley DE, Bray GA, Pi-Sunyer FX, et al. Clinical efficacy of orlistat therapy in overweight and obese patients with insulin-treated type 2 diabetes: a 1-year randomized controlled trial. Diabetes Care 2002 25 : 1033 1041.
29. Scheen AJ, Finer N, Hollander P et al. Efficacy and tolerability of rimonabant in overweight or obese patients with type 2 diabetes: a randomised controlled study. Lancet 2006 368 : 1160 72.
30. Gallwitz B. Glucagon-like peptide-1-based therapies for the treatment of type 2 diabetes mellitus. Treat Endocrinol 2005 4 : 361 70.
31. Buse JB, Henry RR, Han J et al. Effects of exenatide (exendin-4) on glycemic control over 30 weeks in sulfonylurea-treated patients with type 2 diabetes. Diabetes Care 2004 26 : 2628 35.
32. Fineman MS, Bicsak TA, Shen LZ et al. Effect on glycemic control of exenatide (synthetic exendin-4) additive to existing metformin and/or sulfonylurea treatment in patients with type 2 diabetes. Diabetes Care 2003 26 : 2370 7.
33. DeFronzo RA, Ratner RE, Han J et al. Effects of exenatide (exendin-4) on glycemic control and weight over 30 weeks in metformin-treated patients with type 2 diabetes. Diabetes Care 2005 28 : 1092 100.
34. Kendall DM, Riddle MC, Rosenstock J et al. Effects of exenatide (exendin-4) on glycemic control over 30 weeks in patients with type 2 diabetes treated with metformin and a sulfonylurea. Diabetes Care 2005 2 : 1083 91.
35. Kolterman OG, Kim DD, Shen L et al. Pharmacokinetics, pharmacodynamics, and safety of exenatide in patients with type 2 diabetes mellitus. Am J Health Syst Pharm 2005 62 : 173 81.
36. Deacon CF, Ahren B, Holst JJ. Inhibitors of dipepetidyl peptidase IV: a novel approach for the prevention and treatment of type 2 diabetes. Curr Opin Investig Drugs 2004 13 : 1091 102.
37. Herman GA, Bergman A, Liu F et al. Pharmacokinetics and pharmacodynamic effects of the oral DPP-4 inhibitor sitagliptin in middle-aged obese subjects. J Clin Pharmacol 2006 46 : 876 86.
38. Herman GA, Stevens C, Van Dyck K et al. Pharmacokinetics and pharmacodynamics of sitagliptin, an inhibitor of dipeptidyl peptidase IV, in healthy subjects: results from two randomized, double-blind, placebo-controlled studies with single oral doses. Clin Pharmacol Ther 2005 78 : 675 88.
39. Herman GA, Bergman A, Stevens C et al. Effect of single oral doses of sitagliptin, a dipeptidyl peptidase-4 inhibitor, on incretin and plasma glucose levels following an oral glucose tolerance test in patients with type 2 diabetes. J Clin Endocrinol Metab 2006 91 : 4612 9.
40. Herman G, Hanefeld M, Wu M et al. Effect of MK-0431, a dipeptidyl peptidase IV (DPP-IV) inhibitor, on glycemic control after 12 weeks in patients with type 2 diabetes. Diabetes 2005 54 (Suppl. 1 A134 (Abstract 541-P).
41. Aschner P, Kipnes MS, Lunceford JK et al. Effect of the dipeptidyl peptidase-4 inhibitor sitagliptin as monotherapy on glycemic control in patients with type 2 diabetes. Diabetes Care 2006 29 : 2632 7.
42. Charbonnel B, Karasik A, Liu J et al. Efficacy and safety of the dipeptidyl peptidase-4 inhibitor sitagliptin added to ongoing metformin therapy in patients with type 2 diabetes inadequately controlled with metformin alone. Diabetes Care 2006 29 : 2638 43.
43. Rosenstock J, Brazg R, Andryuk PJ et al. Efficacy and safety of the dipeptidyl peptidase-4 inhibitor sitagliptin added to ongoing pioglitazone therapy in patients with type 2 diabetes: a 24-week, multicenter, randomized, double-blind, placebo-controlled, parallel-group study. Clin Ther 2006 28 : 1556 68.
44. He YL, Barilla D, Ligueros-Saylan M et al. The pharmacokinetics and DPP-4 inhibition of LAF237 in healthy volunteers. J Clin Pharmacol 2004 44 : 1212 (Abstract 16).
45. Ahrén B, Landin-Olsson M, Jansson P-A et al. Inhibition of dipeptidyl peptidase-4 reduces glycemia, sustains insulin levels, and reduces glucagon levels in type 2 diabetes. J Clin Endocrinol Metab 2004 89 : 2078 84.
46. He YL, Sabo R, Wang Y. Influence of age, gender and BMI on the pharmacokinetics and pharmacodynamics of vildagliptin. Clin Pharm Ther 2006 79 : P63 (Abstract PIII-19).
47. Ristic S, Byiers S, Foley J, Holmes D. Improved glycaemic control with dipeptidyl peptidase-4 inhibition in patients with type 2 diabetes: vildagliptin (LAF237) dose response. Diabetes Obes Metab 2005 7 : 692 8.
48. Pratley RE, Jauffret-Kamel S, Galbreath E, Holmes D. Twelve-week monotherapy with the DPP-4 inhibitor vildagliptin improves glycemic control in subjects with type 2 diabetes. Horm Metab Res 2006 38 : 423 8.
49. Dejager S, Razac S, Foley JE, Schweizer A. Vildagliptin in drug-naïve patients with type 2 diabetes: a 24-week, double-blind, randomized, placebo-controlled, multiple-dose study. Horm Metab Res 2007 39 : 218 23.
50. Rosenstock J, Baron MA, Dejager S et al. Comparison of vildagliptin and rosiglitazone monotherapy in patients with type 2 diabetes: a 24-week, double-blind, randomized trial. Diabetes Care 2007 30 : 217 23.
51. Ahrén B, Gomis R, Standl E et al. Twelve- and 52-week efficacy of the dipeptidyl peptidase IV inhibitor LAF237 in metformin-treated patients with type 2 diabetes. Diabetes Care 2004 27 : 2874 80.
52. Bosi E, Camisasca RP, Collober C, Rochotte E, Garber AJ. Effects of vildagliptin on glucose control over 24 weeks in patients with type 2 diabetes inadequately controlled with metformin. Diabetes Care 2007 30 : 890 5.
53. Fonseca V, Dejager S, Albrecht D et al. Vildagliptin as add-on to insulin in patients with type 2 diabetes (T2DM). Diabetes 2006 55 (Suppl. 1 A111 (Abstract 467-P).
54. Rosenstock J, Baron MA, Camisasca R-P et al. Efficacy and tolerability of initial combination therapy with vildagliptin and pioglitazone compared with component monotherapy in patients with type 2 diabetes. Diabetes Obes Metab 2007 9 : 175 85.
55. Tran P, Yin H, Smith T, Fischer V. Disposition of [14C]LAF237 in rats and humans. Drug Metab Rev 2002 34 (Suppl. 1 147 (Abstract 293).